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Background: It has been previously reported that IL-22, one of the cytokines secreted by Th17 cells, demonstrates
both a protective and inflammatory promotion effect in inflammatory bowel disease (IBD) through STAT3 signaling
activation. We sought to investigate the role of IL-22 expression in colon cancer (CC).
Methods: The expression of IL-22 and related molecules were detected in human CC, the detail function and
mechanism of IL-22 were investigated by in vivo and in vitro model.
Results: Our results demonstrated significant upregulation of IL-22 in human CC tumor infiltrated leukocytes (TILs)
compared to peripheral lymphocytes. Moreover, our findings demonstrated that IL-22 expression was significantly
higher in ulcerative colitis (UC) tissues versus normal colon tissues. Both IL-22 receptor α1 (IL-22RA1) and IL-23 were
highly expressed in CC and UC tissues compared to normal controls. TILs exhibiting various IL-22 expression levels
isolated from CC patients were demonstrated to enhance tumor growth and metastasis co-transplanted with Hct-
116 cells underwent subcutaneous transplantation in mice model. Tumor growth and metastasis was promoted by
STAT3 phosphorylation and upregulation of its downstream genes such as Bcl-xl, CyclinD1, and VEGF. In vitro
studies confirmed the anti-apoptotic and pro-proliferation effect of IL-22 according to the BrdU cooperation assay
and peroxide induced apoptosis analysis with or without the presence of IL-22.
Conclusion: In this study we demonstrated that excessive IL-22 in the CC and UC microenvironment leads to
tumor growth, inhibition of apoptosis, and promotion of metastasis depend on STAT3 activation.
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Colon cancer (CC) is a common and lethal cancer that
exhibits regional variation in incidence and mortality
around the world. Globally, CC is the third most com-
monly diagnosed cancer in males and the second in fe-
males, with over 1.2 million new cases and 608,700
deaths every year [1]. Ulcerative colitis (UC) is one of
the risk factors for CC. In 1988 it was reported that
sustained UC over a period of 8–10 years significantly
increases the risk of CC by 0.5–1% [2]. Furthermore,
after 40 years of UC, approximately 25–30% of patients
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reproduction in any medium, provided the orstrong link with an inflammatory microenvironment
composed of a large population of normal and premalig-
nant intestinal epithelial cells (IECs) or tumor cells, im-
mune cells, macrophages etc.; the determinants of the
pro- or anti-tumor effect within the microenvironment
have become central in cancer research [4].
Moreover, much of the growth that stimulates the
cross-talk between immune and IECs or malignant cells
is mediated by cytokines that activate the oncogenic
transcription factor STAT3 [5], a major intrinsic activa-
tor in cancer inflammation and a regulator of the tumor
microenvironment [6,7]. STAT3 induces the expression
of genes important for cell cycle progression (such as
cyclinD1 and PCNA) as well as suppression of apoptosis
(Bcl-XL, Bcl-2, and Mcl-1), eventually promoting cell
survival and proliferation during colitis-associated tumo-
rigenesis [7-9]. It has been previously demonstrated thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suppresses cell proliferation and reduces tumor inci-
dence in both a DSS-induced colitis model and colitis
associated cancer (CAC) model [10,11]. Furthermore,
enhanced STAT3 activation has been shown to exhibit
an accelerating effect on CAC development by mutation
of the gp130 receptor [10].
The most famous STAT3 activator, IL-6, is widely recog-
nized to play an inflammation-related role in colon cancer.
In recent years, the involvement of IL-6 in UC and CC has
been an area of active investigation in both experimental
animal models and clinical research [12-15]. Within the
microenvironment of CC or UC, IL-6 originates from vari-
ous cells including IECs and immunocytes, such as Th17
cells. Th17 cells represent a novel subset of T helper cells
that exhibit high expression of RORγT and secrete cyto-
kines, including IL-17A, IL-17 F, IL-21, and IL-22 [9,16-19].
Naïve T cells can be recruited and differentiate into Th17
cells that are polarized by IL-23 in concert with IL-1β, IL-6,
IL-23, TNF-α, and TGF-β, which is abundant in both UC
and CC [20-23]. The role played by Th17 cells in tumor
pathogenesis is controversial and remains unclear. On the
one hand, IL-17 has been demonstrated to be a valuable
marker associated with poor prognosis that promotes
angiogenesis via stimulation of VEGF production of cancer
cells in CC [24,25]. Abundant Foxp3+/IL-17+ T cells have
been detected in CC tissues that exhibited the
capacity to drive cancer initiation in cells with high
levels of phosphorylated Akt and MAPK [26]. On the
other hand, endogenous IL-17 has been shown to
reduce tumor growth and lung metastasis due to the effects
of IFNγ +NK and IFNγ + tumor-specific T cells; these
results suggest that IL-17 potentially promotes protective
tumor immunity [27]. Therefore, further investigation
concerning the role of Th17 cells in CC is warranted.
As one of the cytokines secreted by Th17 cells, the
majority of CC related cytokine studies have reported that
IL-22 is not centrally involved. However, IL-22 was demon-
strated to exhibit general intestinal antimicrobial defense,
regeneration, and protection against injury in a series of
studies by Wolk et al. [28]. Recently, the rs1179251 SNP in
IL-22 was demonstrated to be associated with risk of colon
cancer [29]; Nagakawa et al. demonstrated that IL-22 does
not directly act on immunocompetent cells, and artificially
IL-22 expression in CC cell line can favor apothanasia of
inoculated hosts [30]; An additional two studies were
conducted to investigate the role of IL-22 in UC that
revealed that IL-22 played a pivotal role in UC pathophysi-
ology through both DMBT1 and REGα [31,32]. However,
the specific role of IL-22 in CC remains unclear. Therefore,
we sought to investigate IL-22 expression and the related
molecules in human CC in order to further elucidate
whether IL-22 acts as a tumor promoter and to investigate
the underlying mechanisms of action.Methods
Patients
A total of 82 CC tissues and 40 UC tissues were
investigated in this study, these tissues were obtained
from patients at the time of surgical resection or
endoscopy. Normal colon tissues were obtained from
40 Chinese patients who had suffered from non-
tumor diseases such as tediously long Colon and vas-
cular malformation. All of the cases occurred between
January 2010 and August 2011 at the First Affiliated
Hospital of Nanjing Medical University (Nanjing,
China), and all the samplers were conducted
according to the principles expressed in the Declaration of
Helsinki. Written documented informed consent for
gene expression analyses of all tissues was obtained
from all patients prior to surgery or endoscopy
examination; this study and consent procedure was
approved by the local ethics committee of the First
Affiliated Hospital of Nanjing Medical University.
The diagnosis and staging of colon cancer was
assessed according to the AJCC (TNM) Staging System.
The detailed clinical characteristics of the 82 colon cancer
patients were listed in Table 1.
Isolation and culture of human CC infiltrated leukocytes
The fresh tumor tissues samples were collected from 82
cases of histologically confirmed colon cancer obtained
from hospitalized cancer patients who underwent sur-
gery. The tumor pieces were washed twice in RPMI
1640 (Invitrogen, CA). The fatty, connective, and/or nec-
rotic tissues were removed from the tumor mass in a
10 cm dish. Next, the tissue was cut into 1–2 mm pieces
in RPMI 1640, and the minced tumor pieces were trans-
ferred into a 15-ml or a 50-ml conical tube and incu-
bated with a triple enzyme digestion medium that
contained DNase (30 U/ml), hyaluronidase (0.1 mg/ml),
and collagenase (1 mg/ml) for 2 hours at room
temperature with gentle shaking. The samples were then
resuspended in 10 ml RPMI 1640, filtered through a
70-μm cell strainer (BD), placed into several wells
containing 1 ml of T-cell growth medium (RPMI 1640
with 10% human AB serum, supplemented with 5 U/ml
human rIL-2) in a 24-well plate, the TILs was processed
immediately for IL-22 detection by flow cytometry. To
obtain IL-22(+)TILs, lymphocytes were isolated by flow
cytometry, and maintained in T-cell growth medium. A
polarization stimulation to Th22 cells was performed
according Th22 condition described as previous report
[33] which can be briefly described as 50 ng/ml
TNF-α, 20 ng/ml IL-6, 5 μg/ml anti–IL-12, and 5 μg/ml
anti–IL-4 for 5 days, further mixed with Macrophage
and NK cells isolated from TILs. We nominated this cell
mixture as IL-22 (+) TILs, and preparing for in vitro and
in vivo assays.
Table 1 Clinical characteristics of the 82 colon cancer
patients
Patient characteristics Patients P value*
No. of patients 82 ND

























* by the student's t-test or the Mann–Whitney U test.
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All animal experiments were performed in accordance with
the guidelines of the Animal Care Committee, Nanjing
Medical University. Immunodeficient nude mice (5–6 weeks
of age) were purchased from Charles River Laboratories,
China. All operation concerning animal was performed
according to ARRIVE (Animal Research: Reporting of In
Vivo Experiments) guidelines. Three groups, with 5 mice
each, were injected subcutaneously with three cell mixtures
respectively: Hct-116 cells alone, and Hct-116 cells plus
TILs obtained from each of two CC patients (ratio 1000:1),
respectively, at cell density of 3 × 106 cells in 300 μl saline
solution. Animals were sacrificed 6 weeks after transplant-
ation, and the animals were monitored regularly for tumor
occurrence throughout the entire experiment period.
Quantitative real-time PCR
Reverse transcription reactions were performed using the
SuperScript First-Strand Synthesis System (Invitrogen,CA), and the RNA templates were treated with DNase to
avoid genomic DNA contamination. To determine the
relative level of cDNA in the reverse transcribed samples,
real-time PCR analyses were performed using an Applied
Biosystems 7300 Detection System (Applied Biosystems,
CA). The primers sequence were Forward Primer: GCTT
GACAAGTCCAACTTCCA, Reverse Primer: GCTCACT
CATACTGACTCCGTG, with 140 bp amplification length
for human IL-22, and Forward Primer: AAGGTGA
AGGTCGGAGTCAAC, Reverse Primer: GGGGTCAT
TGATGGCAACAATA, with 102 bp amplification length
for human GAPDH. The primers were synthesized by
Genscript Inc. (Nanjing, China). Real-time PCR reactions
were performed in accordance with the instructions of the
SYBRW Premix Ex Taq™ kit. (Takara, Japan). Data were
normalized with the GAPDH levels in the samples.
Western blot
Proteins were extracted from cell and mouse tissues and
quantified using a protein assay (Bio-Rad Laboratories,
CA). Protein samples (30 μg) were fractionated by SDS-
PAGE and transferred to a nitrocellulose membrane. Im-
munoblotting was conducted using antibodies against
IL-22, IL-22RA1, total STAT3, p-STAT3(S727), Bcl-xl,
CyclinD1, and VEGF (all purchased from Abcam Inc,
MA). The results were visualized via a chemiluminescent
detection system (Pierce ECL Substrate Western blot de-
tection system, Thermo Scientific, IL) and exposure to
autoradiography film (Kodak XAR film).
Immunohistochemistry (IHC)
All the tissues were removed and fixed in 4% parafor-
maldehyde overnight at 4°C, processed, and sectioned at
5 μm thickness. The sectioned slides were stained
immunohistochemically for IL-22, IL-22RA1, IL-23,
CEA, and p-Stat3 (S727) (all purchased from Abcam
Inc., MA) using techniques described previously [34].
Flow cytometry
The peripheral lymphocytes and TILs were stimulated at
37°C for 5 hours with Leukocyte Activation Cocktail (BD
Pharmingen). Thereafter, cells were stained with surface
markers, fixed and permeabilized with IntraPre Reagent
(Beckman Coulter), and finally stained with intracellular
markers. Data were acquired on FACSVantage SE and an-
alyzed with CellQuest software. The fluorochrome-
conjugated mAbs against CD3, CD4, CD8, CD14, CD16,
and CD56 are purchased from BD Pharmingen (CA).
BrdU cooperation and immunofluorescense assay
Hct-116, Hct-116 + TILs, Hct-116 + IL-22(+)TILs, Hct-
116 + IL-22(+)TILs + IL-22mAb, Hct-116 + IL-22(+)TILs +
IL-6mAb (antibodies was all purchased from Abcam Inc.,
MA. 10 μg/ml anti-IL-22 or anti-IL-6 3 hours prior
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(EMD Chemical USA, MA, 5uM for the concentration
of WP1066) were cultured on coverslips such that they
were rapidly dividing. Cells were incubated with 100 μM
BrdU for 2 hours, the medium aspirated, and immedi-
ately fixed and permeabilized in cold methanol:acet-
one (1:1), then blocked with PBS/3% BSA (Sigma-Aldrich,
MO), and incubated with primary BrdU monoclonal
antibody (Sigma-Aldrich) diluted in 3% BSA/PBST (0.2%
Triton X-100). Following incubation with rabbit anti-
mouse FITC-conjugated secondary antibody (Sigma-
Aldrich), slides were mounted in Mounting Medium
(with 1.5 μg/ml DAPI) (Santa Cruz), and visualized
with a fluorescense microscope (Axiovert 200; Zeiss,
Stuttgart, Germany).
Peroxide induced apoptosis and flow cytometry analysis
Hct-116, Hct-116 + TILs, Hct-116 + IL-22(+)TILs, Hct-
116 + IL-22(+)TILs + IL-22mAb, Hct-116 + IL-22(+)TILs +
IL-6mAb and Hct-116 + IL-22(+)TILs +WP1066 (same
treatment to BrdU cooperation assay) were cultured with
complete medium with 0.5 mM peroxide overnight. Next,
the cells were harvested and fixed with 70% cold
EtOH at −20°c overnight, then further analyzed by flow
cytometry (FACSCaliburTM; BD Biosciences, NJ) using a
PI/Annexin staining kit (Invitrogen, CA).
Statistical analysis
The results are expressed as mean ± SD. Comparisons
between two groups were performed using the student’s
t-test or the Mann–Whitney U test, as appropriate. All
statistical analyses were performed using SPSS statisticalFigure 1 Elevated expression of IL-22 was investigated in human colo
(n = 82) from patients suffering from CC, as detected by real-time PCR (unp
by analyzing five fields for each slide evaluated by Image-Pro Plus software
(unpaired t-test). C: Expression and distribution of IL-22 in normal colon tiss
tissues (n = 40), as analyzed by IHC. D1: IL-22 expression in TILs (n = 32) and
D2. Comparison of IL-22 in TILs and corresponding PBMCs (paired t-test). *software (version 13.0), and two-tailed t-tests were ap-
plied to all data unless otherwise specified, with P < 0.05
considered to represent a statistically significant result.
Results
Excessive IL-22 in tissues of colon cancer and ulcerative
colitis
In order to investigate the expression of IL-22 in human
colon cancer, tumor infiltrated leukocytes (TILs), which
are the principal source of IL-22, were isolated from ex-
cised fresh tumor tissues. The total RNA was extracted
from the TILs followed by the cDNA synthesis. Signifi-
cant high expression of IL-22 were detected by real-time
PCR in the TILs samples compared to peripheral blood
mono-nuclear cells (PBMCs) (P = 0.00618, P < 0.01, by
unpaired t-test) (Figure 1A). However, no significant dif-
ference was found between IL-22 expression and varied
groups of clinical characteristics for colon cancer pa-
tients (Table 1). The distribution and localization of IL-
22 proteins was verified by IHC in 82 cases of CC
tissues, 40 cases of normal colon tissues, and 40 cases of
UC tissues in which there was potential chronic inflam-
mation for CC. IL-22 existed in the peri-tumor or non-
parenchymal tissues around the intestinal gland area in
most CC tissues (71 positive in a total of 82 cases, 71/
82) and UC tissues (31/40), whereas normal colon tissue
samples were almost all negative (5/40) (Figure 1B),
which indicated that IL-22 acted as a driver of inflam-
mation based on previous reports in IBD patients [35].
Similar to the findings of real-time PCR analysis, all
slides evaluated by software “Image-plus pro” (Ver. 5.0)
also exhibited a significantly higher positive rate inn cancer (CC). A: Expression of IL-22 in PBMCs (n = 40) and TILs
aired t-test). B: Average integrated optical density (IOD) was obtained
(version 5.0) for IHC staining of IL-22 in CC, UC and normal controls
ues (n = 40), CC tumor tissues (indicated by arrows) (n = 82) and UC
PBMCs (n = 32) by flow cytometry co-stained with antibody to CD3,
* represented P < 0.01 and * represented P < 0.05.
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tissues (CC vs. Normal P = 0.00021, P < 0.01, UC vs.
Normal P = 0.0062, P < 0.01, and CC vs. UC P = 0.0075,
P < 0.01, by unpaired t-test) (Figure 1C). Furthermore,
high expression of IL-22 in CC patients was also con-
firmed by flow cytometry (TILs vs. PBMC P = 0.00068,
by paired t-test) (Figure 1D1, D2).
However, TILs are white blood cells originated from
the blood stream, they are composed of various of in-
flammatory cells, including lymphocytes, macrophages,
natural killer cells (NK) etc. Therefore, in order to iden-
tify the phenotypic features of cells expressing IL-22 in
colon cancer, IL-22 was co-stained with other cellular
surface markers such as CD3, CD4, CD8, CD68, and
CD3 + CD16 + CD56 in 32 cases of TILs isolated from
human colon cancer tissues. This finding indicated that
both CD4 and CD8 positive lymphocytes expressed IL-
22 (4.80 ± 1.81% for CD4 positive cells and 4.01 ± 1.72%
for CD8 positive cells), and a small portion of NK cells
were positive for IL-22 (3.01 ± 1.29%%). A small
population of macrophages (CD68 positive cells,
3.92 ± 1.12%) unexpectedly secreted IL-22 (Figure 2).
We sought to isolate IL-22 expressing TILs for fur-
ther functional studies in accordance with the distri-
bution of IL-22 in TILs. Lymphocytes, macrophages,
and NK cells were isolated by flow cytometry re-
spectively. Lymphocytes were maintained in vitro
after polarizing stimulation to Th22 [33], and then
further mixed with macrophages and NK cells into
a cell mixture, we nominated this cell mixture as
IL-22(+) TILs.Figure 2 A representative case of IL-22 expression in TILs (n = 31) by
and CD3 + CD16 + CD56.IL-22 related proteins are also over-expressed in human
colon cancer and ulcerative colitis
Because IL-22 is one of the hallmark cytokines secreted
by Th17 cells, we analyzed three essential cytokines in
the microenvironment that recruit and induce Th17 pro-
liferation. Numerous studies have verified the level of
IL-1β and TNF-α in human colon cancer [20-23]. Our
findings indicated that expression of IL-23, which has
been rarely reported previously, was detected by IHC
analysis in both CC and UC. These results indicated that
significant upregulation of IL-23 was detected in both
CC and UC (CC vs. Normal control, P = 0.0027, P < 0.01,
and UC vs. Normal control, P = 0.011, P < 0.05, CC vs.
UC, P = 0.017, P < 0.05, by Mann–Whitney U test),
whereas relatively weak expression was detected in only
a small portion of normal colon tissue samples (4/40)
(Figure 3A1, B1-B3). The positive region of IL-23 in CC
and UC was confined mostly to tumor and intestinal
epithelial cells. In addition to IL-23, we identified
another key molecule, IL-22RA1, which is necessary
for signal transmission; the localization was similar to
IL-23 and it was identically overexpressed in tumor
and intestinal epithelial cells of UC (CC vs. Normal
control, P = 0.0044, P < 0.01, and UC vs. Normal control,
P = 0.0084, P < 0.01, CC vs. UC, P = 0.0072, P < 0.01, by
Mann–Whitney U test), whereas it was nearly negative
in normal colon tissues (7/40)(Figure A2, B4-B6). As the
downstream effects of IL-22, activation of STAT3 was
accessed by staining with phosphorylated STAT3 at the
residue of S727. STAT3 was activated in both UC
(34/40) and CC (68/82), which is a significantly higherflow cytometry co-stained with antibody to CD4, CD8, CD68,
Figure 3 IL-22 related proteins are also over-expressed in human colon cancer and ulcerative colitis. A1-A3: Average integrated optical
density (IOD) was obtained by analyzing five fields for each slide evaluated by Image-Pro Plus software (version 5.0) for IHC staining of IL-23, IL-
22RA1, and p-STAT3 (S727) in human CC, UC, and normal colon tissues. B1-3, B4-6 and B7-B9: Expression and distribution of IL-23, IL-22RA1 and
p-STAT3 (S727) in human CC (n = 84), UC (n = 40) and normal colon tissues (n = 40) respectively (Mann–Whitney U test). * represented P < 0.05
and ** represented P < 0.01.
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tissue (3/40) (CC vs. Normal control, P = 0.0051,
P < 0.01, and UC vs. Normal control, P = 0.0081,
P < 0.01, CC vs. UC, P = 0.022, P < 0.05, by Mann–
Whitney U test) (Figure 3A3, B7-B9).
IL-22 is related to promoted tumor growth and
metastasis in vivo
To investigate the effect of IL-22 on tumor growth and
metastasis, we designed an in vivo tumorigenesis assay
using the subcutaneous cell transplantation model. Hct-
116, a colon cancer cell line, was co-transplanted with
TILs isolated from two CC patients with different IL-22
expression levels according to analysis by FCMs
(Figure 4A). Cell suspensions consisting of a 1:1000 cell
mixture ratio (TILs: Hct-116) were injected subcu-
taneously into BALB/c nude mice. TILs from two CC
patients promoted tumor growth and metastasis. Sig-
nificant increase in tumor volume was evident when
Hct-116 cells were co-transplanted with TILs compared
to Hct-116 cells alone; moreover, our findings indicated
that elevated IL-22 expression was correlated to
enhanced tumor volume (TILs1, 1.63 ± 0.23 cm3 vs. Hct-
116, 0.34 ± 0.19 cm3, P = 0.0019, P < 0.01; TILs2, 2.01 ±
0.30 cm3 vs. Hct-116, P = 0.0048, P < 0.01, TILs1 vs.
TILs2, P = 0.022, P < 0.05 by unpaired t-test; Figure 4B1
and B2). Tumor tissue was analyzed by IHC with IL-22
staining, it exhibited that IL-22 expressing TILs isolated
from two patients have proliferated underneath the mice
skin (Figure 4C1, C2). Increased phosphorylation of
STAT3 (S727) in tumor tissues was detected; upregu-
lation of cyclinD1 was also found to be the effect ofthe activation of STAT3 signaling, which potentially
explains the tumor growth enhanced by TILs. BCL-XL, an
anti-apoptosis gene, was similarly elevated in the tumor
tissues with co-transplanted with TILs, which were
also downstream transcripts of STAT3 activation and
potentially explains the tumor growth enhancement
(Figure 4D).
We investigated metastasis by analyzing the lymph
nodes that emerged around the tumor tissue (2/6 in the
TILs1 group and 4/6 in the TILs2). We confirmed that
Hct-116 invaded the lymph nodes with IHC staining for
carcino-embryonic antigen (CEA), which is negative in
normal lymph nodes (Figure 4E). No visceral metastasis
was found in all groups. Based on this result, we ana-
lyzed VEGF expression in the tumor tissues, and our
findings indicated that VEGF expression was elevated in
correlation with TILs (Figure 4D); increased VEGF
expression is also a downstream target of STAT3
activation.
IL-22 enhances tumor proliferation and anti-apoptotic
ability by activating STAT3 signaling in vitro
To further investigate the mechanism of IL-22 on tumor
growth, we utilized in vitro studies (Figure 5A). Hct-116
cells were co-cultured with TILs and IL-22(+)TILs. In
order to exclude the effect of IL-22 secreted by IL-22(+)
TILs, IL-22 was blocked, moreover, the effect of TILs se-
creted IL-6 which can induce activation of STAT3 was
blocked as well, in addition, the expression of both IL-
22 and IL-6 from TILs and IL-22(+)TILs were verified
by ELISA in the supernatant of their cell culture
(Additional file 1: Figure S1). The effects of IL-22 on tumor
Figure 4 IL-22 promotes tumor growth and metastasis in vivo. TILs were isolated from two CC patients and co-transplanted subcutaneously
into nude mice with Hct-116 cells. Tumor growth and metastasis was investigated. A: Different IL-22 expression levels of TILs1 and TILs2 analyzed
by FCMs. B1: Tumor tissues obtained from nude mice from each group. B2: Comparison of tumor volume of each group (unpaired t-test).
C1: IL-22 positive cell distribution in tumor tissues of each group investigated by IHC. C2: Average integrated optical density (IOD) was obtained
by analyzing five fields for each slide evaluated by Image-Pro Plus software (version 5.0) for IHC staining of IL-22. D: Western-blot detection of
expression of p-STAT3 (S727), total STAT3, Bcl-xl, CyclinD1, and VEGF, all normalized to β-actin for every 3 samples in each group. E: IHC staining
of CEA in lymph nodes around the tumor beneath the skin of nude mice. E1 (×40), E2, E3 (×100) and E4 (×200), ** represented P < 0.01.
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gated. The proliferation capability of each group
was assessed by the BrdU cooperation assay. Both
TILs and IL-22(+)TILs significantly enhanced the prolifer-
ation ability of Hct-116 cells (Hct-116 + TILs vs.
Hct-116, P = 0.026, P < 0.05; Hct-116+ IL-22(+)TILs vs.
Hct-116, P = 0.0072, P < 0.01, by unpaired t-test) (Figure 5-
B1-B3, B8); however, when IL-22 and IL-6 were blocked,the percentage of proliferating cells (BrdU positive cells)
decreased dramatically (Figure 5B4, B5 and B8). Addition-
ally, CyclinD1 expression also decreased in correlation
with fewer dividing cells (Figure 5D). IL-22(+)TILs and
TILs also significantly enhanced the anti-apoptosis abil-
ity of Hct-116 cells, which decreased the percentage
of apoptotic cells significantly induced by peroxide in
comparison to Hct-116 cells (Hct-116 + TILs vs. Hct-116,
Figure 5 IL-22 enhances tumor proliferation and anti-apoptosis ability by activating STAT3 signaling in vitro. A: Schematic diagram of
experimental design. B1-B6: Immunofluorescence staining of BrdU in green and DAPI in blue, reflecting cell proliferation in each group detected
by fluorescence microscopy (×200). B7: Immunofluorescense staining with non-specific antibody control (NC) (×200). B8: Comparison of cell
proliferation in each group (the independent co-cultures experiments were repeated in triplicate) (unpaired t-test). C1: Analysis of apoptosis of
Hct-116 cells induced by peroxide in each group by flow cytometry, C2: Comparison of apoptosis in each group (the independent co-cultures
experiments were repeated in triplicate) (unpaired t-test). D. Western-blot detection of IL-22, p-STAT3 (S727), total STAT3, Bcl-XL, Bcl-2, and
CyclinD1 expression, all normalized to the β-actin. *p <0.05; **p < 0.01.
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P = 0.0086, P < 0.01, by unpaired t-test) . However, when
the effect of IL-22 and IL-6 were blocked by their antibody,
apoptosis increased (Figure 5C). To explain this, the anti-
apoptosis gene BCL-XL increased with the existence of TILs
and IL-22(+)TILs, and decreased when IL-22 was blocked
(Figure 5D). To further confirm the effect of IL-22 is depend
on STAT3 activation, WP1066 which is a STAT3 specific in-
hibitor was used, decreased proliferation and increased
apoptosis were investigated even with the existence of IL-22
(+)TILs (WP1106 vs. Hct-116 for BrdU cooperation assay
P = 0.0031, P < 0.01, and for apoptosis assay, P = 0.0047,
P < 0.01, by unpaired t-test) (Figure 5B6, B8 and C). Evidently,
all of these changes were originated from the activation or
blocking of STAT3 signaling. Therefore, in this study, we in-
troduced a STAT3 activator, IL-22, that exhibits a tumor en-
hancement mechanism similar to IL-6.
Discussion
It has been previously demonstrated that IL-22 plays a
protective role within many organs, such as anti-microbial defense, regeneration, and protection against
injury [36,37]. These findings are based on the distribu-
tion of two reporters: IL-22R1 (IL-22RA1) and IL-10R2.
IL-22R1 is located primarily in the skin, digestive tract
(including pancreas and liver), lung, and kidney, while
IL-10R2 is ubiquitously expressed [28,36]. IL-22 acts as
a protector in intestinal mucosal healing through mul-
tiple signaling activation steps. In an intestinal infection
with C. rodentium, IL-22 is produced earlier than IL-
17A and it plays a decisive role, whereas IL-17A does
not [38]. Moreover, Sugimoto et al. demonstrated that
IL-22 contributes to rapid amelioration of local inflam-
mation associated with Th2-mediated colitis [39]. Add-
itionally, studies in genetically engineered mice have
demonstrated that epithelial STAT3 activation in dextran
sodium sulfate colitis is dependent upon IL-22 rather
than IL-6, and that both IL-22 and epithelial STAT3 is
important in wound-healing experiments in vivo [40].
Therefore, according to these studies, most of the pro-
tective roles of IL-22 in the intestinal tract are linked to
STAT3 in IECs, a pleiotropic transcription factor with
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of tissues [41,42]. However, IL-22 has also been consid-
ered an inflammatory driver in IBD based upon both
clinical evidence and mouse model data. Highly elevated
serum levels and a potential systemic role for IL-22 have
been demonstrated to correlate with disease severity in
patients with Crohn’s disease (CD). In 2005 it was shown
that IL-22 was much higher in UC compared to CD, and
a study of human IBD revealed that IL-22 derived from
activated T cells acts on human colonic subepithelial
myofibroblasts to stimulate secretion of proinflammatory
cytokines and matrix-degrading molecules, thus demon-
strating its proinflammatory/remodeling role in IBD [35].
Similar outcomes have been obtained from a colitis mouse
model, indicating that highly elevated IL-22 expression
was an inflammation driver in either a direct or indirect
manner [39,43]. More recently, the role of IL-22 in mouse
IBD and colon cancer have been clarified by Huber et al.
which indicated that the ratio of IL-22/IL-22BP is critical
in regulating intestinal tissue repair and tumorigenesis in
the colon [44].
As discussed above, STAT3 activation by IL-22 plays
both protective and inflammatory driver roles in human
IBD, which is similar to what occurs in the liver. IL-22
demonstrates a directly protective role in acute liver in-
jury, which has been demonstrated by both the Radaeva
and Zenewicz research groups. However, the authors
also hypothesized that the protective effect of IL-22 was
due to activation of STAT3, and that its anti-apoptotic
and regeneration promoting effect potentially contrib-
utes to the development of HCCs [45,46]. This hypoth-
esis was verified by both us and Park et al. recently, and
it has been revealed that IL-22 exhibits opposing short-
term and long-term effects in the liver which in turn
promote cell proliferation, survival, metastasis, and
transformation from chronic hepatitis to HCC [34,47].
Therefore, we investigated whether the opposing effects
of short-term and long-term IL-22 activated STAT3 exist
in the human intestinal tract. Initially, our investigation
confirmed that massive levels of IL-22 were present in
the UC tissues of the Chinese population. Secondly, we
reported for the first time that excessive IL-22 also was
present in human colon cancer. Furthermore, up-
regulation of IL-22 in TILs derived from human CC was
associated with the activation of STAT3 and exhibited
tumor promotion and enhancement of metastasis in
both in vitro and in vivo model.
The tumor microenvironment is composed of tumor
cells, macrophages, and immunocytes etc. where the inter-
actions between these cells involves their secreted cyto-
kines and consists of a free-forward loop with persistent
activation of STAT3 enabling promotion of tumor growth
[7]. Consistent with IL-23 and IL-22RA1, an IL-22 feed-
forward loop in the CC or UC microenvironment hasbeen demonstrated through our research. The IL-22 signal
can be transmitted through a heterodimeric receptor com-
plex that consists of IL-22R1 (IL-22RA1) and IL-10R2
[48,49]. Unlike the ubiquitously expressed IL-10R2 chain,
the IL-22RA1 chain was normally restricted to non-
immune cells such as epithelial cells and hepatocytes [50].
In correlation with overexpression of IL-22 in TILs of CC,
IL-22RA1 is also overexpressed in colon cancer cells and
in IECs of UC, which ensures the transmission of the IL-
22 signal. Pro-tumor cytokine IL-23, which is also regu-
lated by STAT3 [51,52], is over expressed in CC and UC.
Excessive expression of IL-23 plus TNF-α, IL-6, and IL-1β,
which have already been demonstrated to be overexpressed
in human CC, composed a milieu for infiltrated naive lym-
phocytes which were also enrolled by STAT3 activation to
differentiate to Th17 cells expressing IL-22 [20-23]. In this
study, we transplanted this IL-22 related tumor microenvir-
onment beneath the skin of nude mice. The proliferation
and metastasis enhancing effects of this free-forward loop
were confirmed, and proliferation associated cyclinD1, cell
survival associated BCL-XL, and metastasis associated
VEGF were all upregulated and mediated by STAT3 activa-
tion, which was demonstrated by phosphorylation of S727
residue [9,52]. Furthermore, these tumor growth and metas-
tasis promotional effects of IL-22 were demonstrated to
occur in a dose-dependent manner when various tumor mi-
croenvironments were transplanted with a range of IL-22
levels. We investigated more precise and accurate mecha-
nisms with in vitro studies utilizing the IL-22 and IL-6 de-
pletion assay; cell survival and tumor promotion was
eliminated when IL-22 was blocked based upon the attenu-
ated activation of STAT3 which is similar to IL-6, Moreover,
the specialty of IL-22 effect through STAT3 signaling was
verified by using STAT3 inhibitor WP1066.Conclusion
This study revealed a previously unknown role of IL-22
in human UC and CC, which potentially enhances pro-
liferation, cell survival, and metastasis. Further studies
are warranted to investigate the potential of anti-IL-22
therapeutics for the prevention and treatment of human
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